Dazukibart, a type I interferon inhibitor, reduced dermatomyositis disease severity while maintaining a well-tolerated safety ...

Dermatomyositis (DM) is a chronic autoimmune disease characterized by inflammatory myopathy and distinctive skin ...

Dazukibart, an anti–interferon beta monoclonal antibody, showed potential in reducing dermatomyositis symptoms, with significant improvements in skin disease activity.